Skip to main content
Clinical Trials/ACTRN12612000884808
ACTRN12612000884808
Completed
Phase 2

Among patients with a mid trimester fetal demise, does the use of mifepristone prior to misoprostol, compared with misoprostol alone, reduce the time to delivery?

Emma Allanson0 sites232 target enrollmentAugust 20, 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Management of second trimester fetal demise
Sponsor
Emma Allanson
Enrollment
232
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 20, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Emma Allanson

Eligibility Criteria

Inclusion Criteria

  • All women who are admitted to King Edward Memorial Hospital for Women for pregnancy interruption for fetal death in utero between 14 and 28 weeks gestation will be invited to participate in the study

Exclusion Criteria

  • Women with more than three previous caesarean sections
  • Women not able to understand English
  • Multi fetal gestations

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
effect of simple zofa (hyssopus officinalis) syrup on persistant asthma
IRCT20110811007297N5Shiraz University of Medical Sciences60
Not yet recruiting
Phase 3
Comparison of different types of Injectable iron in the treatment of Iron Deficiency AnemiaHealth Condition 1: D509- Iron deficiency anemia, unspecified
CTRI/2023/01/048725Armed Forces Medical College
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of age
EUCTR2013-003535-30-GBGlaxoSmithKline Biologicals1,220
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of age
EUCTR2013-003535-30-DEGlaxoSmithKline Biologicals1,220
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageVaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).MedDRA version: 18.1Level: PTClassification code 10069613Term: Varicella immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10069628Term: Varicella immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10063315Term: Varicella zoster virus DNA test positiveSystem Organ Class: 100000004848MedDRA version: 18.0Level: LLTClassification code 10046983Term: Varicella zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: PTClassification code 10046980Term: VaricellaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: LLTClassification code 10050331Term: Varicella-like rashSystem Organ Class: 100000004858MedDRA version: 18.0Level: LLTClassification code 10063144Term: Varicella zoster virus serology positiveSystem Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2013-003535-30-EEGlaxoSmithKline Biologicals1,220